Search social media for injury recovery and you will find BPC-157 everywhere. The peptide is promoted as a tendon, ligament and gut healer, and it is popular with athletes and biohackers. Now ask how many humans have actually been studied. A new systematic review in Acta Orthopaedica Belgica puts the answer at 30 people, across three studies.
That is the gap between the hype and the evidence, and it is the main finding of the paper.
What the Review Did
The authors (Poolton, Minett and Kazmi) ran a PRISMA-compliant systematic review, prospectively registered with PROSPERO (CRD420261406325). They searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to 1 June 2026. They accepted quantitative and qualitative studies of BPC-157 for any indication in human participants.
They then assessed study quality with the NIH Quality Assessment Tool for Before-After Studies With No Control Group. They graded certainty of evidence with GRADE and synthesised results narratively, following SWiM guidance.
The search was broad, and a broad search of the major databases and trial registries turned up three eligible human studies.
The Three Studies Behind the Hype
| Study | Design | Condition and route | Participants |
|---|---|---|---|
| 1 | Retrospective | Knee pain, intra-articular injection | 16 |
| 2 | Retrospective pilot | Interstitial cystitis, intravesical (into the bladder) | 12 |
| 3 | Prospective pilot | Safety evaluation, intravenous | 2 |
Together that is 30 people.
Only one of the three studies concerns a musculoskeletal problem, and it is a retrospective look at 16 knee-pain patients. The cystitis study is a bladder condition. The intravenous study enrolled two people.
The tendon-repair and "heal anything" reputation of BPC-157 rests mainly on animal models. The human data in this review barely touch it.
The Headline Result, and Why It Misleads
All three studies reported symptom improvement in most participants and no treatment-related adverse events. Read alone, that sounds like a success story.
The authors did not read it that way. They judged all three studies to be of poor methodological quality, and they rated overall certainty of evidence as very low under GRADE, citing serious risk of bias, indirectness and imprecision.
Here is why "improved, with no side effects" carries so little weight here:
- No control group. The review used a tool designed for before-after studies without controls. Without a comparison arm, you cannot separate a drug effect from placebo response, natural recovery, regression to the mean, or other treatments given at the same time. Knee pain and interstitial cystitis both fluctuate, and both respond strongly to placebo.
- Retrospective design. Two of the three studies looked back at records. Retrospective data are prone to selection bias and incomplete follow-up, and people who did poorly may simply be missing.
- Tiny samples. With 30 people in total, and as few as 2 in one study, rare or delayed adverse events could not show up even if they existed. "None seen" in 12 or 16 people says very little about what happens in thousands.
- Indirectness. The studies used different conditions and routes of administration (joint, bladder, vein). Results from one cannot be carried over to the others, or to the oral and subcutaneous use that many consumers actually try.
- Safety isn't the same as no reported events. An absence of reported harm in small, uncontrolled studies is not evidence of safety. It means harm was not detected.
Not Approved, and Not Simple to Source
The authors describe BPC-157 as a synthetic pentadecapeptide that lacks regulatory approval for human use. Several practical issues follow:
- It is a research peptide. It is sold as a research chemical, not a licensed medicine.
- Quality is uncertain. Grey-market products have no guaranteed purity, dose accuracy or sterility, and these are the very things a regulator would check. Even if the peptide were safe in a clean study, what a buyer receives may differ from it.
- Legal status varies. Rules differ by country and by whether a product is sold for human use, so check local law.
- It is prohibited in sport. BPC-157 is on the World Anti-Doping Agency's Prohibited List as a non-approved substance. Tested athletes risk sanctions.
What This Means for You
Dose, timing and duration: The abstract does not give dosing details, and this article will not invent a protocol. No human dose has been validated by a controlled trial, so there is no evidence-based dose or timing to recommend.
- Tested or competitive athletes, because of the WADA prohibition.
- Anyone pregnant, breastfeeding or trying to conceive, since nothing is known about these groups.
- People with a cancer history or active cancer, or with serious chronic conditions, where the effects of an unstudied bioactive compound are unknown.
- Anyone considering injections, particularly intravenous or intra-articular ones, where contamination or poor-quality product carries real risk.
- Anyone on other medications, because interactions have not been studied.
Who it is for: On current evidence, nobody outside a regulated clinical trial. The authors conclude that BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.
If you have a stubborn tendon or joint injury: Evidence-based options such as progressive loading rehabilitation and assessment by a sports medicine clinician have far more human data behind them.
What Real Evidence Would Look Like
Moving from "30 people" to credible evidence would take:
- Randomised, blinded, placebo-controlled trials in a defined condition, such as a specific tendinopathy.
- Pre-registered endpoints, with validated pain and function scores and imaging where relevant.
- Pharmaceutical-grade, verified product, with documented dose and purity.
- Adequate sample size and follow-up, to detect both benefit and uncommon harms.
- Formal safety monitoring and transparent reporting of all adverse events.
The Bottom Line
BPC-157's reputation is built mostly on animal research, and the best human summary to date comes to 30 participants, no control groups and very-low-certainty evidence. The finding of improvement without adverse events is interesting enough to justify proper trials. It does not show that the peptide works or that it is safe.
This article is for information only and is not medical advice. Talk to a qualified clinician before using any unapproved compound.
